{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:30:06Z","timestamp":1791599406551,"version":"4.3.4"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Chem Res"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00044-026-03607-5","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T07:18:40Z","timestamp":1786691920000},"page":"1667-1689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Indole-based derivatives as anticancer agents: recent advances in structure\u2013activity relationships and biological mechanisms"],"prefix":"10.1007","volume":"35","author":[{"given":"Aashik","family":"Malik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai Parkash","family":"Kadian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ramsha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Manisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Rathour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"3607_CR1","doi-asserted-by":"publisher","unstructured":"Yakkala PA, Erram V, Begum SA, Kamal A, Royal Society of Chemistry. Recent developments in the discovery of indole-based scaffolds as promising targeted cancer therapeutics. RSC Med Chem. 2025. . https:\/\/doi.org\/10.1039\/d5md00849b","DOI":"10.1039\/d5md00849b"},{"key":"3607_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin Wiley. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin Wiley"},{"key":"3607_CR3","doi-asserted-by":"publisher","unstructured":"Zhang S, Xiao X, Yi Y, Wang X, Zhu L, Shen Y, et al. Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets. Signal Transduction and Targeted Therapy 2024 9:1 [Internet]. Volume 9. Nature Publishing Group; 2024. pp. 149\u2013. [cited 2026 Jul 29];. https:\/\/doi.org\/10.1038\/s41392-024-01848-7.","DOI":"10.1038\/s41392-024-01848-7"},{"key":"3607_CR4","doi-asserted-by":"publisher","unstructured":"Hanahan D. Hallmarks of cancer\u2014Then and now, and beyond. Cell [Internet]. Volume 189. Cell; 2026. pp. 2254\u201377. [cited 2026 Jul 6]. https:\/\/doi.org\/10.1016\/j.cell.2025.12.049.","DOI":"10.1016\/j.cell.2025.12.049"},{"key":"3607_CR5","doi-asserted-by":"publisher","unstructured":"Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nat Nat Publishing Group. 2019;299\u2013309. https:\/\/doi.org\/10.1038\/s41586-019-1730-1.","DOI":"10.1038\/s41586-019-1730-1"},{"key":"3607_CR6","doi-asserted-by":"publisher","unstructured":"Ewieda SY, Ahmed EM, Gohar NA, Ibrahim SG, Essa MA, Nemr MTM. Design, synthesis, and antitumor evaluation of new pyridazinone scaffolds as dual EGFR\/VEGFR-2 kinase inhibitors and apoptotic cells inducers. Bioorg Chem [Internet]. Academic Press; 2025 [cited 2026 Jul 31];166:109157. https:\/\/doi.org\/10.1016\/J.BIOORG.2025.109157","DOI":"10.1016\/J.BIOORG.2025.109157"},{"key":"3607_CR7","doi-asserted-by":"publisher","unstructured":"Kumar A, Singh AK, Singh H, Vijayan V, Kumar D, Naik J, et al. Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective. Pharmaceuticals. MDPI; 2023. https:\/\/doi.org\/10.3390\/ph16020299.","DOI":"10.3390\/ph16020299"},{"key":"3607_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158117","author":"O Ebenezer","year":"2022","unstructured":"Ebenezer O, Jordaan MA, Carena G, Bono T, Shapi M, Tuszynski JA, MDPI. An Overview of the Biological Evaluation of Selected Nitrogen-Containing Heterocycle Medicinal Chemistry Compounds. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23158117.","journal-title":"Int J Mol Sci"},{"key":"3607_CR9","doi-asserted-by":"publisher","unstructured":"Nemr MTM, Fadaly WAA, Abdelaziz MA. Pharmaceutical Applications of Di\/Tri-Aryl Pyrazole Derivatives: A Review on Recent Updates. ChemistrySelect [Internet]. John Wiley and Sons Inc; 2025 [cited 2026 Jul 31];10:e04601. https:\/\/doi.org\/10.1002\/SLCT.202504601;WEBSITE:WEBSITE:CHEMISTRY-EUROPE;WGROUP:STRING:PUBLICATION.","DOI":"10.1002\/SLCT.202504601"},{"key":"3607_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2022.100606","author":"E Kabir","year":"2022","unstructured":"Kabir E, Uzzaman M. A review on biological and medicinal impact of heterocyclic compounds. Results Chem Elsevier B. 2022. https:\/\/doi.org\/10.1016\/j.rechem.2022.100606. .V.","journal-title":"Results Chem Elsevier B"},{"key":"3607_CR11","doi-asserted-by":"publisher","unstructured":"Padmapriya M, Hakkimane SS, Gaonkar SL. Synthetic approaches, emerging applications, and challenges of indole-based five-membered heterocycles in medicinal chemistry. Discover Applied Sciences. Springer Nature; 2025. https:\/\/doi.org\/10.1007\/s42452-025-06598-x.","DOI":"10.1007\/s42452-025-06598-x"},{"key":"3607_CR12","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.4067\/s0717-97072020000204900","volume":"65","author":"H Sachdeva","year":"2020","unstructured":"Sachdeva H, Mathur J, Guleria A. Indole derivatives as potential anticancer agents: A review. J Chil Chem Soc Sociedad Chil de Quim. 2020;65:4900\u20137. https:\/\/doi.org\/10.4067\/s0717-97072020000204900.","journal-title":"J Chil Chem Soc Sociedad Chil de Quim"},{"key":"3607_CR13","doi-asserted-by":"publisher","unstructured":"Barresi E, Robello M, Baglini E, Poggetti V, Viviano M, Salerno S, et al. Indol-3-ylglyoxylamide as Privileged Scaffold in Medicinal Chemistry. Pharmaceuticals. Multidisciplinary Digital Publishing Institute (MDPI); 2023. https:\/\/doi.org\/10.3390\/ph16070997.","DOI":"10.3390\/ph16070997"},{"key":"3607_CR14","doi-asserted-by":"publisher","first-page":"13383","DOI":"10.1039\/D2NJ00460G","volume":"46","author":"YAAM Elshaier","year":"2022","unstructured":"Elshaier YAAM, Nemr MTM, Refaey MS, Fadaly WAA, Barakat A. Chemistry of 2-vinylindoles: synthesis and applications. New J Chem [Internet] Royal Soc Chem. 2022;46:13383\u2013400. 10.1039\/D2NJ00460G. https:\/\/doi.org\/10.1039\/D2NJ00460G","journal-title":"New J Chem [Internet] Royal Soc Chem"},{"key":"3607_CR15","doi-asserted-by":"publisher","unstructured":"Hassan SM, Farid A, Panda SS, Bekheit MS, Dinkins H, Fayad W, et al. Indole Compounds in Oncology: Therapeutic Potential and Mechanistic Insights. Pharmaceuticals. Multidisciplinary Digital Publishing Institute (MDPI); 2024. https:\/\/doi.org\/10.3390\/ph17070922.","DOI":"10.3390\/ph17070922"},{"key":"3607_CR16","doi-asserted-by":"publisher","unstructured":"Teraiya N, Agrawal K, Patel TM, Patel A, Patel S, Shah U, et al. A Review of the Therapeutic Importance of Indole Scaffold in Drug Discovery. Curr Drug Discov Technol. Bentham Science Publishers Ltd.; 2023. p. 20. https:\/\/doi.org\/10.2174\/1570163820666230505120553.","DOI":"10.2174\/1570163820666230505120553"},{"key":"3607_CR17","doi-asserted-by":"publisher","unstructured":"Dhuguru J, Skouta R. Role of indole scaffolds as pharmacophores in the development of anti-lung cancer agents. Molecules. MDPI AG; 2020. https:\/\/doi.org\/10.3390\/molecules25071615.","DOI":"10.3390\/molecules25071615"},{"key":"3607_CR18","doi-asserted-by":"publisher","unstructured":"Mo X, Rao DP, Kaur K, Hassan R, Abdel-Samea AS, Farhan SM, et al. Indole Derivatives: A Versatile Scaffold in Modern Drug Discovery\u2014An Updated Review on Their Multifaceted Therapeutic Applications (2020\u20132024). Molecules. Multidisciplinary Digital Publishing Institute (MDPI); 2024. https:\/\/doi.org\/10.3390\/molecules29194770.","DOI":"10.3390\/molecules29194770"},{"key":"3607_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1055\/a-0809-5098","volume":"69","author":"S Saini","year":"2019","unstructured":"Saini S. Synthesis and Anticonvulsant Studies of Thiazolidinone and Azetidinone Derivatives from Indole Moiety. Drug Res Georg Thieme Verlag. 2019;69:445\u201350. https:\/\/doi.org\/10.1055\/a-0809-5098.","journal-title":"Drug Res Georg Thieme Verlag"},{"key":"3607_CR20","doi-asserted-by":"publisher","unstructured":"Nisha N, Singh S, Sharma N, Chandra R. The indole nucleus as a selective COX-2 inhibitor and anti-inflammatory agent (2011\u20132022). Organic Chemistry Frontiers. Royal Society of Chemistry; 2022. pp. 3624\u201339. https:\/\/doi.org\/10.1039\/d2qo00534d.","DOI":"10.1039\/d2qo00534d"},{"key":"3607_CR21","doi-asserted-by":"publisher","unstructured":"Pacheco PAF, Santos MMM. Recent Progress in the Development of Indole-Based Compounds Active against Malaria, Trypanosomiasis and Leishmaniasis. Molecules. MDPI; 2022. https:\/\/doi.org\/10.3390\/molecules27010319.","DOI":"10.3390\/molecules27010319"},{"key":"3607_CR22","doi-asserted-by":"publisher","unstructured":"Bajad NG, Singh SK, Singh SK, Singh TD, Singh M, Indole. A promising scaffold for the discovery and development of potential anti-tubercular agents. Current Research in Pharmacology and Drug Discovery. Elsevier B.V.; 2022. https:\/\/doi.org\/10.1016\/j.crphar.2022.100119.","DOI":"10.1016\/j.crphar.2022.100119"},{"key":"3607_CR23","doi-asserted-by":"publisher","unstructured":"Girgis AS, Panda SS, Kariuki BM, Bekheit MS, Barghash RF, Aboshouk DR. Indole-Based Compounds as Potential Drug Candidates for SARS-CoV-2. Molecules. Multidisciplinary Digital Publishing Institute (MDPI); 2023. https:\/\/doi.org\/10.3390\/molecules28186603.","DOI":"10.3390\/molecules28186603"},{"key":"3607_CR24","doi-asserted-by":"publisher","unstructured":"Zeng W, Han C, Mohammed S, Li S, Song Y, Sun F et al. Indole-containing pharmaceuticals: targets, pharmacological activities, and SAR studies. RSC Med. Chem. Royal Society of Chemistry; 2024. pp. 788\u2013808. https:\/\/doi.org\/10.1039\/d3md00677h","DOI":"10.1039\/d3md00677h"},{"key":"3607_CR25","doi-asserted-by":"publisher","first-page":"794","DOI":"10.30574\/wjarr.2022.16.3.1378","volume":"16","author":"S Vishesh Verma","year":"2022","unstructured":"Vishesh Verma S, Sharma K, Gaur N, Kumar. Role of vinca alkaloids and their derivatives in cancer therapy. World J Adv Res Reviews GSC Online Press. 2022;16:794\u2013800. https:\/\/doi.org\/10.30574\/wjarr.2022.16.3.1378.","journal-title":"World J Adv Res Reviews GSC Online Press"},{"key":"3607_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112359","author":"Y Jia","year":"2020","unstructured":"Jia Y, Wen X, Gong Y, Wang X. Current scenario of indole derivatives with potential anti-drug-resistant cancer activity. Eur J Med Chem Elsevier Masson SAS. 2020. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112359.","journal-title":"Eur J Med Chem Elsevier Masson SAS"},{"key":"3607_CR27","doi-asserted-by":"publisher","unstructured":"Karimabad MN, Mahmoodi M, Jafarzadeh A, Darekordi A, Hajizadeh MR, Hassanshahi G, Molecular, Targets. Anti-cancer Properties and Potency of Synthetic Indole-3-carbinol Derivatives. Mini-Reviews in Medicinal Chemistry. Volume 19. Bentham Science Publishers Ltd.; 2018. pp. 540\u201354. https:\/\/doi.org\/10.2174\/1389557518666181116120145.","DOI":"10.2174\/1389557518666181116120145"},{"key":"3607_CR28","doi-asserted-by":"publisher","unstructured":"Fang Z, Meng Q, Xu J, Wang W, Zhang B, Liu J et al. Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives. Cancer Commun. John Wiley and Sons Inc; 2023. pp. 3\u201341. https:\/\/doi.org\/10.1002\/cac2.12392","DOI":"10.1002\/cac2.12392"},{"key":"3607_CR29","doi-asserted-by":"publisher","unstructured":"Badria FA, Soliman SM, Atef S, Islam MS, Al-Majid AM, Dege N, et al. Anticancer indole-based chalcones: A structural and theoretical analysis. Molecules MDPI AG. 2019;24. https:\/\/doi.org\/10.3390\/molecules24203728.","DOI":"10.3390\/molecules24203728"},{"key":"3607_CR30","doi-asserted-by":"publisher","unstructured":"Alhilal M, Alhilal S, Gomha SM, Farag B, Sabancilar I, Ouf SA. Biological evaluation and molecular docking studies of novel aza-acyclic nucleosides as putative antimicrobial, anticancer, and antioxidant agents. BMC Chemistry. 2025 19:1 [Internet]. BioMed Central; 2025 [cited 2026 Jul 31];19:255-. https:\/\/doi.org\/10.1186\/S13065-025-01623-X","DOI":"10.1186\/S13065-025-01623-X"},{"key":"3607_CR31","doi-asserted-by":"publisher","unstructured":"Kamel MM, Abdel-hameid MK, El-Nassan HB, El-Khouly EA. Synthesis and Cytotoxic Activity of Novel Mono- and Bis-Indole Derivatives: Analogues of Marine Alkaloid Nortopsentin. Med Chem (Los Angeles) [Internet]. Volume 17. Bentham Science Publishers Ltd.; 2020. pp. 779\u201389. [cited 2026 Jul 29];. https:\/\/doi.org\/10.2174\/1573406416666200509235305.","DOI":"10.2174\/1573406416666200509235305"},{"key":"3607_CR32","doi-asserted-by":"publisher","unstructured":"Rana M, Ranjan R, Ghosh NS, Kumar D, Singh R. A Review on Indole as a Cardinal Scaffold for Anticancer Drugs Development. Curr Cancer Ther Rev [Internet]. Volume 20. Bentham Science Publishers Ltd.; 2023. pp. 372\u201385. [cited 2026 Jul 29];. https:\/\/doi.org\/10.2174\/0115733947249518231001001728.","DOI":"10.2174\/0115733947249518231001001728"},{"key":"3607_CR33","doi-asserted-by":"publisher","unstructured":"Kaur B, Venugopal S, Verma A, Sahu SK, Wadhwa P, Kumar D et al. Recent Developments in the Synthesis and Anticancer Activity of Indole and Its Derivatives. Curr Org Synth [Internet]. Curr Org Synth; 2023 [cited 2026 Jul 29];20:376\u201394. https:\/\/doi.org\/10.2174\/1570179419666220509215722","DOI":"10.2174\/1570179419666220509215722"},{"key":"3607_CR34","doi-asserted-by":"publisher","unstructured":"Sridhar BT, Gunavanthrao Yernale N, Gani RS, Gupta N, Ganachari SV, Suliphuldevara Mathada B. A concise review on recent development of indole derivatives for anticancer activities. Journal of the Indian Chemical Society [Internet]. Elsevier; 2024 [cited 2026 Jul 29];101:101282. https:\/\/doi.org\/10.1016\/J.JICS.2024.101282","DOI":"10.1016\/J.JICS.2024.101282"},{"key":"3607_CR35","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1080\/17568919.2025.2521250","volume":"17","author":"Ling He","year":"2025","unstructured":"Ling H, Congcong Z. The current landscape of indole hybrids with in vivo antitumor potential. Future Med Chem [Internet]. Taylor and Francis Ltd.; 2025 [cited 2026 Jul 29];17:1489. https:\/\/doi.org\/10.1080\/17568919.2025.2521250","journal-title":"Future Medicinal Chemistry"},{"key":"3607_CR36","doi-asserted-by":"publisher","unstructured":"Barresi E, Baglini E, Poggetti V, Castagnoli J, Giorgini D, Salerno S, et al. Indole-Based Compounds in the Development of Anti-Neurodegenerative Agents. Molecules. Multidisciplinary Digital Publishing Institute (MDPI); 2024. https:\/\/doi.org\/10.3390\/molecules29092127.","DOI":"10.3390\/molecules29092127"},{"key":"3607_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111691","author":"Y Wan","year":"2019","unstructured":"Wan Y, Li Y, Yan C, Yan M, Tang Z, Indole. A privileged scaffold for the design of anti-cancer agents. Eur J Med Chem Elsevier Masson SAS. 2019. https:\/\/doi.org\/10.1016\/j.ejmech.2019.111691.","journal-title":"Eur J Med Chem Elsevier Masson SAS"},{"key":"3607_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23074001","author":"O Ebenezer","year":"2022","unstructured":"Ebenezer O, Shapi M, Tuszynski JA. A Review of the Recent Developments of Molecular Hybrids Targeting Tubulin Polymerization. Int J Mol Sci MDPI. 2022. https:\/\/doi.org\/10.3390\/ijms23074001.","journal-title":"Int J Mol Sci MDPI"},{"key":"3607_CR39","doi-asserted-by":"publisher","unstructured":"Silva Morat\u00f3rio de Moraes R, Mestre Botelho AB, Tavares de Almeida Pinto G, Couto Rodrigues S, Miranda Martins MT, Alves Soares DL. Chemistry, Applications, and Synthesis Methods of Indole Derivatives: A Comprehensive Review. The Chemical Record. John Wiley & Sons, Ltd; 2025 https:\/\/doi.org\/10.1002\/tcr.202500121","DOI":"10.1002\/tcr.202500121"},{"key":"3607_CR40","doi-asserted-by":"publisher","unstructured":"Russo E, Grondona C, Brullo C, Spallarossa A, Villa C, Tasso B. Indole Antitumor Agents in Nanotechnology Formulations: An Overview. Pharmaceutics. Multidisciplinary Digital Publishing Institute (MDPI); 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15071815.","DOI":"10.3390\/pharmaceutics15071815"},{"key":"3607_CR41","doi-asserted-by":"publisher","unstructured":"Kumar P, Ahmad MI, Singh S, Pratama MRF, Mishra AK. Recent advancements on biological activity of indole and their derivatives: A review. Thai Journal of Pharmaceutical Sciences. Faculty of Pharmaceutical Sciences. Chulalongkorn University; 2022. pp. 233\u201350. https:\/\/doi.org\/10.56808\/3027-7922.2567.","DOI":"10.56808\/3027-7922.2567"},{"key":"3607_CR42","doi-asserted-by":"publisher","unstructured":"Mubassir M, Ahamad N, Kumar A. Exploring the Versatile Pharmacological Potential of Indole Derivatives: A Comprehensive Review. Progress in Chemical and Biochemical Research [Internet]. Volume 8. Sami Publishing Company; 2025. pp. 257\u201369. [cited 2026 Jul 9];. https:\/\/doi.org\/10.48309\/pcbr.2025.511003.1402.","DOI":"10.48309\/pcbr.2025.511003.1402"},{"key":"3607_CR43","doi-asserted-by":"publisher","unstructured":"Debnath B, Nandi B, Paul S, Manna S, Maity A, Bandyopadhyay K, et al. Novel indole-based synthetic molecules in cancer treatment: Synthetic strategies and structure-activity relationship. Med. Drug Discov. Elsevier B.V.; 2025. https:\/\/doi.org\/10.1016\/j.medidd.2025.100208.","DOI":"10.1016\/j.medidd.2025.100208"},{"key":"3607_CR44","doi-asserted-by":"publisher","unstructured":"Dr\u0103goi CM, Nicolae A-C, Dumitrescu I-B. The Indole Scaffold in Biochemistry and Therapeutics: A Privileged Structure with Diverse Chemical, Biological, and Clinical Significance. Targets [Internet]. Volume 4. Multidisciplinary Digital Publishing Institute; 2026. p. 4. [cited 2026 Jul 2];. https:\/\/doi.org\/10.3390\/targets4010004.","DOI":"10.3390\/targets4010004"},{"key":"3607_CR45","doi-asserted-by":"publisher","unstructured":"Dhiman A, Sharma R, Singh RK. Target-based anticancer indole derivatives and insight into structure\u2013activity relationship: A mechanistic review update (2018\u20132021). Acta Pharm. Sin. B. Chinese Academy of Medical Sciences; 2022. pp. 3006\u201327. https:\/\/doi.org\/10.1016\/j.apsb.2022.03.021","DOI":"10.1016\/j.apsb.2022.03.021"},{"key":"3607_CR46","doi-asserted-by":"publisher","unstructured":"Asati V, Bhupal R, Bhattacharya S, Kaur K, Gupta G, Pathak A, et al. Recent Updates on Indole Derivatives as Kinase Inhibitors in the Treatment of Cancer. Anticancer Agents Med Chem [Internet]. Volume 23. Bentham Science Publishers Ltd.; 2022. pp. 404\u201316. [cited 2026 Jul 3];. https:\/\/doi.org\/10.2174\/1871520622666220607143040.","DOI":"10.2174\/1871520622666220607143040"},{"key":"3607_CR47","doi-asserted-by":"publisher","unstructured":"Jin P, Liao M, Liu H, Huang K, Fu L, Jin X. Activating protein kinases to treat diseases: Current understanding and future challenges. Acta Pharm Sin B [Internet]. Chinese Academy of Medical Sciences; 2025 [cited 2026 Jun 12];16:746. https:\/\/doi.org\/10.1016\/j.apsb.2025.12.004","DOI":"10.1016\/j.apsb.2025.12.004"},{"key":"3607_CR48","doi-asserted-by":"publisher","unstructured":"Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Targeting cancer with kinase inhibitors. J Clin Invest [Internet]. American Society for Clinical Investigation; 2015 [cited 2026 Jun 12];125:1780. https:\/\/doi.org\/10.1172\/jci76094","DOI":"10.1172\/jci76094"},{"key":"3607_CR49","doi-asserted-by":"publisher","unstructured":"Kumar R, Goel H, Solanki R, Rawat L, Tabasum S, Tanwar P et al. Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy. Med Drug Discov [Internet]. Elsevier; 2024 [cited 2026 Jun 3];23:100195. https:\/\/doi.org\/10.1016\/j.medidd.2024.100195","DOI":"10.1016\/j.medidd.2024.100195"},{"key":"3607_CR50","doi-asserted-by":"publisher","unstructured":"Ou X, Gao G, Habaz IA, Wang Y. Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies. MedComm (Beijing) [Internet]. John Wiley and Sons Inc; 2024 [cited 2026 Jun 12];5:e694. https:\/\/doi.org\/10.1002\/mco2.694","DOI":"10.1002\/mco2.694"},{"key":"3607_CR51","doi-asserted-by":"publisher","unstructured":"Baldi S, Long N, Ma S, Liu L, Al-Danakh A, Yang Q, et al. Advancements in Protein Kinase Inhibitors: From Discovery to Clinical Applications. Research [Internet]. Volume 8. American Association for the Advancement of Science (AAAS); 2025. p. 0747. [cited 2026 Jul 3];. https:\/\/doi.org\/10.34133\/research.0747.","DOI":"10.34133\/research.0747"},{"key":"3607_CR52","doi-asserted-by":"publisher","unstructured":"Li J, Gong C, Zhou H, Liu J, Xia X, Ha W et al. Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives. Int J Mol Sci [Internet]. Multidisciplinary Digital Publishing Institute; 2024 [cited 2026 Jul 3];25:5489. https:\/\/doi.org\/10.3390\/ijms25105489","DOI":"10.3390\/ijms25105489"},{"key":"3607_CR53","doi-asserted-by":"publisher","unstructured":"Xu Z, Li R, Ding K, Wang Y, Zhuang Y. An insight into the in vivo antitumor therapeutic potential of indole-(fused) pyri(mi)dine hybrids. Future Med Chem [Internet]. Taylor and Francis Ltd.; 2025 [cited 2026 Jul 5];17:1155. https:\/\/doi.org\/10.1080\/17568919.2025.2504336","DOI":"10.1080\/17568919.2025.2504336"},{"key":"3607_CR54","doi-asserted-by":"publisher","unstructured":"Mishra S, Sahu A, Kaur A, Kaur M, Kumar J, Wal P. Recent Development in the Search for Epidermal Growth Factor Receptor (EGFR) Inhibitors based on the Indole Pharmacophore. Curr Top Med Chem [Internet]; 2023;24:581\u2013613 . https:\/\/doi.org\/10.2174\/0115680266264206231020111820","DOI":"10.2174\/0115680266264206231020111820"},{"key":"3607_CR55","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.2174\/1389557516666160321114917","volume":"16","author":"D Singh","year":"2016","unstructured":"Singh D, Attri BK, Gill RK, Bariwal J. Review on EGFR Inhibitors: Critical Updates. Mini-Reviews in Medicinal Chemistry. Bentham Sci Publishers. 2016;16:1134\u201366. https:\/\/doi.org\/10.2174\/1389557516666160321114917.","journal-title":"Bentham Sci Publishers"},{"key":"3607_CR56","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.3390\/ijms24032651","volume":"24","author":"T Zubair","year":"2023","unstructured":"Zubair T, Bandyopadhyay D, Small Molecule EGFR. Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities. Int J Mol Sci [Internet]. 2023;24:2651. https:\/\/doi.org\/10.3390\/ijms24032651. [cited 2026 Jul 3];. Multidisciplinary Digital Publishing Institute.","journal-title":"Int J Mol Sci [Internet]"},{"key":"3607_CR57","doi-asserted-by":"publisher","unstructured":"Abourehab MAS, Alqahtani AM, Youssif BGM, Gouda AM, Globally Approved EGFR, Inhibitors. Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism. Molecules [Internet]. Volume 26. Multidisciplinary Digital Publishing Institute; 2021. p. 6677. [cited 2026 Jul 3];. https:\/\/doi.org\/10.3390\/molecules26216677.","DOI":"10.3390\/molecules26216677"},{"key":"3607_CR58","doi-asserted-by":"publisher","unstructured":"Mohamed FAM, Gomaa HAM, Hendawy OM, Ali AT, Farghaly HS, Gouda AM, et al. Design, synthesis, and biological evaluation of novel EGFR inhibitors containing 5-chloro-3-hydroxymethyl-indole-2-carboxamide scaffold with apoptotic antiproliferative activity. Bioorg Chem Acad Press Inc. 2021;112. https:\/\/doi.org\/10.1016\/j.bioorg.2021.104960.","DOI":"10.1016\/j.bioorg.2021.104960"},{"key":"3607_CR59","doi-asserted-by":"publisher","unstructured":"Al-Wahaibi LH, Mostafa YA, Abdelrahman MH, El-Bahrawy AH, Trembleau L, Youssif BGM. Synthesis and Biological Evaluation of Indole-2-Carboxamides with Potent Apoptotic Antiproliferative Activity as EGFR\/CDK2 Dual Inhibitors. Pharmaceuticals MDPI. 2022;15. https:\/\/doi.org\/10.3390\/ph15081006.","DOI":"10.3390\/ph15081006"},{"key":"3607_CR60","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1134\/s1070428025600846","volume":"61","author":"NVNK Ganesh Babu","year":"2025","unstructured":"Ganesh Babu NVNK, Sudha M, Subramanyam S, Allaka TR. Development of Novel Indole\u20131,3,4-Oxadiazole Hybrids Targeting EGFR in Lung Cancer: Synthesis, Anticancer Evaluation, and Computational Study. Russian J Org Chem Pleiades Publishing. 2025;61:2332\u201348. https:\/\/doi.org\/10.1134\/s1070428025600846.","journal-title":"Russian J Org Chem Pleiades Publishing"},{"key":"3607_CR61","doi-asserted-by":"publisher","unstructured":"Mahmoud E, Abdelhamid D, Youssif BGM, Gomaa HAM, Hayallah AM, Abdel-Aziz M. Design, synthesis, and antiproliferative activity of new indole\/1,2,4-triazole\/chalcone hybrids as EGFR and\/or c-MET inhibitors. Arch Pharm (Weinheim). John Wiley and Sons Inc; 2024. p. 357. https:\/\/doi.org\/10.1002\/ardp.202300562.","DOI":"10.1002\/ardp.202300562"},{"key":"3607_CR62","doi-asserted-by":"publisher","unstructured":"Aboelez O, Belal M, Xiang A, Ma G. X. Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFRWT and EGFRT790M. J Enzyme Inhib Med Chem [Internet]. Taylor & Francis; 2022 [cited 2026 Jul 30];37:1196\u2013211. https:\/\/doi.org\/10.1080\/14756366.2022.2062338","DOI":"10.1080\/14756366.2022.2062338"},{"key":"3607_CR63","doi-asserted-by":"publisher","unstructured":"Ahmed AM, Aboelez MO, Ezelarab HAA, Khodairy A, Hassan A, User MA et al. New S- and N-alkyl functionalized bis-1,2,4-Triazolyl-based derivatives as potential dual EGFRWT and EGFRT790M inhibitors: Synthesis, anti-proliferative evaluation, molecular docking study and ADMET studies. J Mol Struct [Internet]. Elsevier; 2025 [cited 2026 Jul 30];1324:140720. https:\/\/doi.org\/10.1016\/J.MOLSTRUC.2024.140720","DOI":"10.1016\/J.MOLSTRUC.2024.140720"},{"key":"3607_CR64","doi-asserted-by":"publisher","unstructured":"Aboelez MO, El-Remaily MAEAAA, Kamel MS, Al kamaly O, Fadaly WAA, Nemr MTM et al. Novel 3,4-diaminothieno[2,3-b]thiophene-2,5-dicarbohydrazide-based scaffolds as EGFRWT, EGFRT790M, and tubulin polymerization inhibitors with anti-proliferative activity. Bioorg Chem [Internet]. Academic Press; 2025 [cited 2026 Jul 30];163:108728. https:\/\/doi.org\/10.1016\/J.BIOORG.2025.108728","DOI":"10.1016\/J.BIOORG.2025.108728"},{"key":"3607_CR65","doi-asserted-by":"publisher","unstructured":"Lorenc P, Sikorska A, Molenda S, Guzniczak N, Dams-Kozlowska H, Florczak A. Physiological and tumor-associated angiogenesis: Key factors and therapy targeting VEGF\/VEGFR pathway. Biomedicine & Pharmacotherapy [Internet]. Volume 180. Elsevier Masson; 2024. p. 117585. [cited 2026 Jul 4];. https:\/\/doi.org\/10.1016\/j.biopha.2024.117585.","DOI":"10.1016\/j.biopha.2024.117585"},{"key":"3607_CR66","doi-asserted-by":"publisher","unstructured":"Patel SA, Nilsson MB, Le X, Cascone T, Jain RK, Heymach JV. Molecular Mechanisms and Future Implications of VEGF\/VEGFR in Cancer Therapy. Clin Cancer Res [Internet]. Volume 29. American Association for Cancer Research Inc.; 2023. p. 30. [cited 2026 Jul 4];. https:\/\/doi.org\/10.1158\/1078-0432.ccr-22-1366.","DOI":"10.1158\/1078-0432.ccr-22-1366"},{"key":"3607_CR67","doi-asserted-by":"publisher","unstructured":"Shah FH, Nam YS, Bang JY, Hwang IS, Kim DH, Ki M et al. Targeting vascular endothelial growth receptor-2 (VEGFR-2): structural biology, functional insights, and therapeutic resistance. Arch Pharm Res [Internet]. Springer; 2025 [cited 2026 Jul 4];48:404\u201325. https:\/\/doi.org\/10.1007\/s12272-025-01545-1","DOI":"10.1007\/s12272-025-01545-1"},{"key":"3607_CR68","doi-asserted-by":"publisher","unstructured":"Abdelgawad MA, Hayallah AM, Bukhari SNA, Musa A, Elmowafy M, Abdel-Rahman HM, et al. Design, Synthesis, Molecular Modeling, and Anticancer Evaluation of New VEGFR-2 Inhibitors Based on the Indolin-2-One Scaffold. Pharmaceuticals MDPI. 2022;15. https:\/\/doi.org\/10.3390\/ph15111416.","DOI":"10.3390\/ph15111416"},{"key":"3607_CR69","doi-asserted-by":"publisher","first-page":"18872","DOI":"10.1021\/acsomega.0c02038","volume":"5","author":"S Mohamady","year":"2020","unstructured":"Mohamady S, Galal M, Eldehna WM, Gutierrez DC, Ibrahim HS, Elmazar MM, et al. Dual Targeting of VEGFR2 and C-Met Kinases via the Design and Synthesis of Substituted 3-(Triazolo-thiadiazin-3-yl)indolin-2-one Derivatives as Angiogenesis Inhibitors. ACS Omega Am Chem Soc. 2020;5:18872\u201386. https:\/\/doi.org\/10.1021\/acsomega.0c02038.","journal-title":"ACS Omega Am Chem Soc"},{"key":"3607_CR70","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1039\/d5md00332f","volume":"16","author":"AF El-Mokadem","year":"2025","unstructured":"El-Mokadem AF, Abd El-Gaber MK, Chung PH, Koh SB, Hassan HY, Youssef AF. Design, synthesis, molecular modeling, and antiproliferative evaluation of new 2-oxoindolin-3-ylidene thiazole derivatives. RSC Med Chem Royal Soc Chem. 2025;16:3645\u201370. https:\/\/doi.org\/10.1039\/d5md00332f.","journal-title":"RSC Med Chem Royal Soc Chem"},{"key":"3607_CR71","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41392-024-02080-z","volume":"10","author":"I Pellarin","year":"2025","unstructured":"Pellarin I, Dall\u2019Acqua A, Favero A, Segatto I, Rossi V, Crestan N, et al. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduct Target Ther [Internet]. 2025;10:11. https:\/\/doi.org\/10.1038\/s41392-024-02080-z","journal-title":"Signal Transduct Target Ther [Internet]"},{"key":"3607_CR72","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/14728222.2025.2537412","volume":"29","author":"MK Chen","year":"2025","unstructured":"Chen MK, Luo L, Massoumi N, Keyomarsi K. Targeting CDK2 and other novel cell cycle targets for breast cancer therapy. Expert Opin Ther Targets [Internet] Taylor Francis Ltd. 2025;29:435. https:\/\/doi.org\/10.1080\/14728222.2025.2537412","journal-title":"Expert Opin Ther Targets [Internet] Taylor Francis Ltd"},{"key":"3607_CR73","doi-asserted-by":"publisher","unstructured":"Gupta J, Saeed BI, Bishoyi AK, Alkhathami AG, Asliddin S, Nathiya D et al. From cell cycle control to cancer therapy: exploring the role of CDK1 and CDK2 in tumorigenesis. Medical Oncology [Internet]. Springer; 2025 [cited 2026 Jul 4];42:422-. https:\/\/doi.org\/10.1007\/s12032-025-02973-1","DOI":"10.1007\/s12032-025-02973-1"},{"key":"3607_CR74","doi-asserted-by":"publisher","unstructured":"Mohamed-Ezzat RA, Al-Ashmawy AAK, Srour AM. Novel indole-based scaffolds: Design, synthesis, molecular modeling, and anti-proliferative evaluation. BMC Chem BioMed Cent Ltd. 2026;20. https:\/\/doi.org\/10.1186\/s13065-026-01776-3.","DOI":"10.1186\/s13065-026-01776-3"},{"key":"3607_CR75","doi-asserted-by":"publisher","unstructured":"Al-Warhi T, El Kerdawy AM, Aljaeed N, Ismael OE, Ayyad RR, Eldehna WM, et al. Synthesis, biological evaluation and in silico studies of certain oxindole\u2013indole conjugates as anticancer CDK inhibitors. Molecules MDPI AG. 2020;25. https:\/\/doi.org\/10.3390\/molecules25092031.","DOI":"10.3390\/molecules25092031"},{"key":"3607_CR76","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13008-018-0040-6","volume":"13","author":"E Willems","year":"2018","unstructured":"Willems E, Dedobbeleer M, Digregorio M, Lombard A, Lumapat PN, Rogister B. The functional diversity of Aurora kinases: a comprehensive review. Cell Div [Internet] BioMed Cent. 2018;13:7\u2013. https:\/\/doi.org\/10.1186\/s13008-018-0040-6. [cited 2026 Jul 5];.","journal-title":"Cell Div [Internet] BioMed Cent"},{"key":"3607_CR77","doi-asserted-by":"publisher","unstructured":"D\u2019Assoro AB, Haddad T, Galanis E, Frontiers Media SA. 2016 [cited 2026 Jul 5];5:295. https:\/\/doi.org\/10.3389\/fonc.2015.00295","DOI":"10.3389\/fonc.2015.00295"},{"key":"3607_CR78","doi-asserted-by":"publisher","unstructured":"Chung S, Sperier E, Graciano K, Hu X, Guo H, Xu J. Aurora kinases, emerging critical targets for cancer treatment and related new therapeutic strategies. Bioorg Chem [Internet]. Academic Press; 2025 [cited 2026 Jul 5];163:108633. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108633","DOI":"10.1016\/j.bioorg.2025.108633"},{"key":"3607_CR79","doi-asserted-by":"publisher","unstructured":"Xie B, Shi M, Tang D, Yang S, Zeng Y, Nie L et al. Design and Synthesis of Novel Indolinone Aurora B Kinase Inhibitors Based on Fragment-Based Drug Discovery (FBDD). Mol Divers [Internet]. 2025 [cited 2026 Jul 12];30:4015\u201330. https:\/\/doi.org\/10.1007\/s11030-025-11353-w","DOI":"10.1007\/s11030-025-11353-w"},{"key":"3607_CR80","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1039\/d4md00373j","volume":"16","author":"YL Jiao","year":"2024","unstructured":"Jiao YL, Zhong J, Xu JF, Ning SB, Liang TG, Zhao MZ, et al. Design and synthesis of (E)-3-benzylideneindolin-2-one derivatives as potential allosteric inhibitors of Aurora A kinase. RSC Med Chem Royal Soc Chem. 2024;16:826\u201334. https:\/\/doi.org\/10.1039\/d4md00373j.","journal-title":"RSC Med Chem Royal Soc Chem"},{"key":"3607_CR81","doi-asserted-by":"publisher","unstructured":"Tang S, Zhou Z, Jiang Z, Zhu W, Qiao D. Indole-Based Tubulin Inhibitors: Binding Modes and SARs Investigations. Molecules [Internet]. MDPI; 2022 [cited 2026 Jul 6];27:1587. https:\/\/doi.org\/10.3390\/molecules27051587","DOI":"10.3390\/molecules27051587"},{"key":"3607_CR82","doi-asserted-by":"publisher","unstructured":"Wang X, Gigant B, Zheng X, Chen Q. Microtubule-targeting agents for cancer treatment: Seven binding sites and three strategies. MedComm \u2013 Oncology [Internet]. Volume 2. Wiley, Ltd;; 2023. p. e46. [cited 2026 Jul 6];. https:\/\/doi.org\/10.1002\/mog2.46.","DOI":"10.1002\/mog2.46"},{"key":"3607_CR83","doi-asserted-by":"publisher","unstructured":"Wittmann C, Sivchenko AS, Bacher F, Tong KKH, Guru N, Wilson T, et al. Inhibition of Microtubule Dynamics in Cancer Cells by Indole-Modified Latonduine Derivatives and Their Metal Complexes. Inorg Chem [Internet]. Volume 61. American Chemical Society; 2022. p. 1456. [cited 2026 Jul 6];. https:\/\/doi.org\/10.1021\/acs.inorgchem.1c03154.","DOI":"10.1021\/acs.inorgchem.1c03154"},{"key":"3607_CR84","doi-asserted-by":"publisher","first-page":"19738","DOI":"10.18632\/oncotarget.14980","volume":"8","author":"E Di Cesare","year":"2017","unstructured":"Di Cesare E, Verrico A, Miele A, Giubettini M, Rovella P, Coluccia A, et al. Mitotic cell death induction by targeting the mitotic spindle with tubulin-inhibitory indole derivative molecules. Oncotarget [Internet] Impact Journals LLC. 2017;8:19738. https:\/\/doi.org\/10.18632\/oncotarget.14980. [cited 2026 Jul 6];.","journal-title":"Oncotarget [Internet] Impact Journals LLC"},{"key":"3607_CR85","doi-asserted-by":"publisher","unstructured":"Shi L, Yang S, Chang J, Zhang Y, Liu W, Zeng J, et al. Design, synthesis and biological evaluation of 9-aryl-5H-pyrido[4,3-b]indole derivatives as potential tubulin polymerization inhibitors. Front Chem Front Media S A. 2022;10. https:\/\/doi.org\/10.3389\/fchem.2022.1004835.","DOI":"10.3389\/fchem.2022.1004835"},{"key":"3607_CR86","doi-asserted-by":"publisher","unstructured":"Mahmoud E, Abdelhamid D, Mohammed AF, Almarhoon ZM, Br\u00e4se S, Youssif BGM, et al. Design, Synthesis, and Antiproliferative Activity of Novel Indole\/1,2,4-Triazole Hybrids as Tubulin Polymerization Inhibitors. Pharmaceuticals. Multidisciplinary Digital Publishing Institute (MDPI); 2025. p. 18. https:\/\/doi.org\/10.3390\/ph18020275.","DOI":"10.3390\/ph18020275"},{"key":"3607_CR87","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.compbiolchem.2019.05.002","volume":"80","author":"F Kazan","year":"2019","unstructured":"Kazan F, Yagci ZB, Bai R, Ozkirimli E, Hamel E, Ozkirimli S. Synthesis and biological evaluation of indole-2-carbohydrazides and thiazolidinyl-indole-2-carboxamides as potent tubulin polymerization inhibitors. Comput Biol Chem Elsevier Ltd. 2019;80:512\u201323. https:\/\/doi.org\/10.1016\/j.compbiolchem.2019.05.002.","journal-title":"Comput Biol Chem Elsevier Ltd"},{"key":"3607_CR88","doi-asserted-by":"publisher","unstructured":"Talukdar A, Kundu B, Sarkar D, Goon S, Mondal MA. Topoisomerase I inhibitors: Challenges, progress and the road ahead. Eur J Med Chem [Internet]. Elsevier Masson; 2022 [cited 2026 Jul 29];236:114304. https:\/\/doi.org\/10.1016\/J.EJMECH.2022.114304","DOI":"10.1016\/J.EJMECH.2022.114304"},{"key":"3607_CR89","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nrm.2016.111","volume":"17","author":"Y Pommier","year":"2016","unstructured":"Pommier Y, Sun Y, Huang SYN, Nitiss JL. Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. Nat Rev Mol Cell Biol [Internet] Nat Publishing Group. 2016;17:703\u201321. https:\/\/doi.org\/10.1038\/nrm.2016.111. [cited 2026 Jul 6];.","journal-title":"Nat Rev Mol Cell Biol [Internet] Nat Publishing Group"},{"key":"3607_CR90","doi-asserted-by":"publisher","unstructured":"Yakkala PA, Penumallu NR, Shafi S, Kamal A. Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents. Pharmaceuticals [Internet]. Multidisciplinary Digital Publishing Institute (MDPI); 2023 [cited 2026 Jul 6];16:1456. https:\/\/doi.org\/10.3390\/ph16101456","DOI":"10.3390\/ph16101456"},{"key":"3607_CR91","doi-asserted-by":"publisher","unstructured":"Bax BD, Murshudov G, Maxwell A, Germe T. DNA Topoisomerase Inhibitors: Trapping a DNA-Cleaving Machine in Motion. J Mol Biol [Internet]. Academic Press; 2019 [cited 2026 Jul 30];431:3427\u201349. https:\/\/doi.org\/10.1016\/J.JMB.2019.07.008","DOI":"10.1016\/J.JMB.2019.07.008"},{"key":"3607_CR92","doi-asserted-by":"publisher","unstructured":"Bondarev AD, Jonsson J, Chubarev VN, Tarasov VV, Lagunas-Rangel FA, Schi\u00f6th HB. Recent developments of topoisomerase inhibitors: Clinical trials, emerging indications, novel molecules and global sales. Pharmacol Res [Internet]. Academic Press; 2024 [cited 2026 Jul 7];209:107431. https:\/\/doi.org\/10.1016\/j.phrs.2024.107431","DOI":"10.1016\/j.phrs.2024.107431"},{"key":"3607_CR93","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ejmech.2018.07.028","volume":"156","author":"Y Xu","year":"2018","unstructured":"Xu Y, Wu L, Rashid HU, Jing D, Liang X, Wang H, et al. Novel indolo-sophoridinic scaffold as Topo I inhibitors: Design, synthesis and biological evaluation as anticancer agents. Eur J Med Chem Elsevier Masson SAS. 2018;156:479\u201392. https:\/\/doi.org\/10.1016\/j.ejmech.2018.07.028.","journal-title":"Eur J Med Chem Elsevier Masson SAS"},{"key":"3607_CR94","doi-asserted-by":"publisher","unstructured":"Kadagathur M, Devi GP, Grewal P, Sigalapalli DK, Makhal PN, Banerjee UC, et al. Novel diindoloazepinone derivatives as DNA minor groove binding agents with selective topoisomerase I inhibition: Design, synthesis, biological evaluation and docking studies. Bioorg Chem Acad Press Inc. 2020;99. https:\/\/doi.org\/10.1016\/j.bioorg.2020.103629.","DOI":"10.1016\/j.bioorg.2020.103629"},{"key":"3607_CR95","doi-asserted-by":"publisher","unstructured":"Okoro CO, Fatoki TH, A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents. International Journal of Molecular Sciences. 2023, Vol 24, Page 2532 [Internet]. Multidisciplinary Digital Publishing Institute; 2023 [cited 2026 Jul 29];24:2532. https:\/\/doi.org\/10.3390\/IJMS24032532","DOI":"10.3390\/IJMS24032532"},{"key":"3607_CR96","doi-asserted-by":"publisher","unstructured":"Lee JH, Berger JM. Cell Cycle-Dependent Control and Roles of DNA Topoisomerase II. Genes. 2019, Vol 10, Page 859 [Internet]. Multidisciplinary Digital Publishing Institute; 2019 [cited 2026 Jul 29];10:859. https:\/\/doi.org\/10.3390\/GENES10110859","DOI":"10.3390\/GENES10110859"},{"key":"3607_CR97","doi-asserted-by":"publisher","unstructured":"Shen G, Li S, Zhu Y, Xu Z, Liu X, Lv C et al. Recent progress in topoisomerase inhibitors as anticancer agents: Research and design strategies for Topo I and II inhibitors via structural optimization. Bioorg Chem [Internet]. Academic Press; 2025 [cited 2026 Jul 6];165:109040. https:\/\/doi.org\/10.1016\/j.bioorg.2025.109040","DOI":"10.1016\/j.bioorg.2025.109040"},{"key":"3607_CR98","doi-asserted-by":"publisher","unstructured":"Li AL, Hao Y, Wang WY, Liu QS, Sun Y, Gu W. Design, synthesis, and anticancer evaluation of novel indole derivatives of ursolic acid as potential topoisomerase II inhibitors. Int J Mol Sci MDPI AG. 2020;21. https:\/\/doi.org\/10.3390\/ijms21082876.","DOI":"10.3390\/ijms21082876"},{"key":"3607_CR99","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1002\/ddr.21976","volume":"83","author":"K Haider","year":"2022","unstructured":"Haider K, Sharma S, Pokharel YR, Das S, Joseph A, Najmi AK, et al. Synthesis, biological evaluation, and in silico studies of indole-tethered pyrazoline derivatives as anticancer agents targeting topoisomerase II\u03b1. Drug Dev Res John Wiley Sons Inc. 2022;83:1555\u201377. https:\/\/doi.org\/10.1002\/ddr.21976.","journal-title":"Drug Dev Res John Wiley Sons Inc"},{"key":"3607_CR100","doi-asserted-by":"publisher","first-page":"371","DOI":"10.33545\/26164485.2024.V8.I4F.1311","volume":"8","author":"BP Ajeesha","year":"2024","unstructured":"Ajeesha BP, Apoptosis V. An overview of programmed cell death. Int J Homoeopathic Sci [Internet] Integr Publishers. 2024;8:371\u20133 https:\/\/doi.org\/10.33545\/26164485.2024.V8.I4F.1311","journal-title":"Int J Homoeopathic Sci [Internet] Integr Publishers"},{"key":"3607_CR101","doi-asserted-by":"publisher","unstructured":"Castillo Ferrer C, Berthenet K, Ichim G. Apoptosis \u2013 Fueling the oncogenic fire. FEBS J [Internet]. John Wiley and Sons Inc; 2020 [cited 2026 Jul 7];288:4445. https:\/\/doi.org\/10.1111\/febs.15624","DOI":"10.1111\/febs.15624"},{"key":"3607_CR102","doi-asserted-by":"publisher","unstructured":"Mustafa M, Ahmad R, Tantry IQ, Ahmad W, Siddiqui S, Alam M et al. Apoptosis: A Comprehensive Overview of Signaling Pathways, Morphological Changes, and Physiological Significance and Therapeutic Implications. Cells [Internet]. Multidisciplinary Digital Publishing Institute (MDPI); 2024 [cited 2026 Jul 7];13:1838. https:\/\/doi.org\/10.3390\/cells13221838","DOI":"10.3390\/cells13221838"},{"key":"3607_CR103","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/j.1365-2184.2012.00845.x","volume":"45","author":"L Ouyang","year":"2012","unstructured":"Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif [Internet]. 2012;45:487. https:\/\/doi.org\/10.1111\/j.1365-2184.2012.00845.x. [cited 2026 Jul 7];.","journal-title":"Cell Prolif [Internet]"},{"key":"3607_CR104","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.2174\/1871520621999210104192644\/CITE\/REFWORKS","volume-title":"Recent Development in Indole Derivatives as Anticancer Agent: A Mechanistic Approach. Anticancer Agents Med Chem [Internet]","author":"N Devi","year":"2021","unstructured":"Devi N, Kaur K, Biharee A, Jaitak V. Recent Development in Indole Derivatives as Anticancer Agent: A Mechanistic Approach. Anticancer Agents Med Chem [Internet]. Volume 21. : Bentham Science Publishers Ltd.; 2021. pp. 1802\u201324. https:\/\/doi.org\/10.2174\/1871520621999210104192644\/CITE\/REFWORKS"},{"key":"3607_CR105","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-022-01350-z","volume":"15","author":"R Qin","year":"2022","unstructured":"Qin R, You FM, Zhao Q, Xie X, Peng C, Zhan G, et al. Naturally derived indole alkaloids targeting regulated cell death (RCD) for cancer therapy: from molecular mechanisms to potential therapeutic targets. J Hematol Oncol [Internet] BioMed Cent. 2022;15:133\u2013. https:\/\/doi.org\/10.1186\/s13045-022-01350-z. [cited 2026 Jul 8];.","journal-title":"J Hematol Oncol [Internet] BioMed Cent"},{"key":"3607_CR106","doi-asserted-by":"publisher","first-page":"417","DOI":"10.4161\/cbt.9.6.11392","volume":"9","author":"B Leibowitz","year":"2010","unstructured":"Leibowitz B, Yu J. Mitochondrial signaling in cell death via the Bcl-2 family. Cancer Biol Ther [Internet] Landes Bioscience. 2010;9:417. https:\/\/doi.org\/10.4161\/cbt.9.6.11392","journal-title":"Cancer Biol Ther [Internet] Landes Bioscience"},{"key":"3607_CR107","doi-asserted-by":"publisher","unstructured":"Pe\u00f1a-Blanco A, Garc\u00eda-S\u00e1ez AJ, Bax. Bak and beyond \u2014 mitochondrial performance in apoptosis. FEBS Journal [Internet]. Volume 285. Blackwell Publishing Ltd; 2018. pp. 416\u201331. [cited 2026 Jul 7];. https:\/\/doi.org\/10.1111\/febs.14186.","DOI":"10.1111\/febs.14186"},{"key":"3607_CR108","doi-asserted-by":"publisher","unstructured":"Kalkavan H, Green DR. MOMP, cell suicide as a BCL-2 family business. Cell Death Differ [Internet]. Nature Publishing Group; 2017 [cited 2026 Jul 7];25:46\u201355. https:\/\/doi.org\/10.1038\/cdd.2017.179","DOI":"10.1038\/cdd.2017.179"},{"key":"3607_CR109","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1080\/14756366.2017.1421181","volume":"33","author":"WM Eldehna","year":"2018","unstructured":"Eldehna WM, Abo-Ashour MF, Ibrahim HS, Al-Ansary GH, Ghabbour HA, Elaasser MM, et al. Novel [(3-indolylmethylene)hydrazono]indolin-2-ones as apoptotic anti-proliferative agents: design, synthesis and in vitro biological evaluation. J Enzyme Inhib Med Chem Taylor Francis Ltd. 2018;33:686\u2013700. https:\/\/doi.org\/10.1080\/14756366.2017.1421181.","journal-title":"J Enzyme Inhib Med Chem Taylor Francis Ltd"},{"key":"3607_CR110","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/14756366.2020.1862100","volume":"36","author":"WM Eldehna","year":"2021","unstructured":"Eldehna WM, Abo-Ashour MF, Al-Warhi T, Al-Rashood ST, Alharbi A, Ayyad RR, et al. Development of 2-oindolin-3-ylidene-indole-3-carbohydrazide derivatives as novel apoptotic and anti-proliferative agents towards colorectal cancer cells. J Enzyme Inhib Med Chem Taylor Francis Ltd. 2021;36:319\u201328. https:\/\/doi.org\/10.1080\/14756366.2020.1862100.","journal-title":"J Enzyme Inhib Med Chem Taylor Francis Ltd"},{"key":"3607_CR111","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/cdd.2017.186","volume":"25","author":"J Kale","year":"2017","unstructured":"Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ [Internet] Nat Publishing Group. 2017;25:65\u201380. https:\/\/doi.org\/10.1038\/cdd.2017.186. [cited 2026 Jul 8];.","journal-title":"Cell Death Differ [Internet] Nat Publishing Group"},{"key":"3607_CR112","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1472-6750-13-45","volume":"13","author":"J Long","year":"2013","unstructured":"Long J, Liu L, Nikolovska-Coleska Z, Shangary S, Yi H, Wang S, et al. Optimization and validation of mitochondria-based functional assay as a useful tool to identify BH3-like molecules selectively targeting anti-apoptotic Bcl-2 proteins. BMC Biotechnol [Internet]. 2013;13:45. https:\/\/doi.org\/10.1186\/1472-6750-13-45. [cited 2026 Jul 8];.","journal-title":"BMC Biotechnol [Internet]"},{"key":"3607_CR113","doi-asserted-by":"publisher","unstructured":"Hata AN, Engelman JA, Faber AC. The BCL-2 family: key mediators of the apoptotic response to targeted anti-cancer therapeutics. Cancer Discov [Internet]. American Association for Cancer Research Inc.; 2015 [cited 2026 Jul 8];5:475. https:\/\/doi.org\/10.1158\/2159-8290.cd-15-0011","DOI":"10.1158\/2159-8290.cd-15-0011"},{"key":"3607_CR114","doi-asserted-by":"publisher","unstructured":"Almehdi AM, Soliman SSM, El-Shorbagi ANA, Westwell AD, Hamdy R. Design, Synthesis, and Potent Anticancer Activity of Novel Indole-Based Bcl-2 Inhibitors. Int J Mol Sci Multidisciplinary Digit Publishing Inst (MDPI). 2023;24. https:\/\/doi.org\/10.3390\/ijms241914656.","DOI":"10.3390\/ijms241914656"},{"key":"3607_CR115","doi-asserted-by":"publisher","first-page":"13925","DOI":"10.1021\/acs.jmedchem.4c00643","volume":"67","author":"H Deng","year":"2024","unstructured":"Deng H, Zhang J, Liu L, Zhang H, Han Y, Wu L, et al. Discovery of Novel Mcl-1 Inhibitors with a 3-Substituted-1H-indole-1-yl Moiety Binding to the P1-P3 Pockets to Induce Apoptosis in Acute Myeloid Leukemia Cells. J Med Chem Am Chem Soc. 2024;67:13925\u201358. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00643.","journal-title":"J Med Chem Am Chem Soc"},{"key":"3607_CR116","doi-asserted-by":"publisher","unstructured":"Chen HP, Zhao YT, Zhao TC. Histone Deacetylases and Mechanisms of Regulation of Gene Expression (Histone deacetylases in cancer). Crit Rev Oncog [Internet]. Volume 20. Begell House Inc.; 2015. p. 35. [cited 2026 Jul 8];. https:\/\/doi.org\/10.1615\/critrevoncog.2015012997.","DOI":"10.1615\/critrevoncog.2015012997"},{"key":"3607_CR117","doi-asserted-by":"publisher","unstructured":"Alseksek RK, Ramadan WS, Saleh E, El-Awady R. The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention. Int J Mol Sci [Internet]. Multidisciplinary Digital Publishing Institute; 2022 [cited 2026 Jul 8];23:8141. https:\/\/doi.org\/10.3390\/ijms23158141","DOI":"10.3390\/ijms23158141"},{"key":"3607_CR118","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1756-8722-3-5","volume":"3","author":"J Tan","year":"2010","unstructured":"Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol [Internet]. 2010;3:5. https:\/\/doi.org\/10.1186\/1756-8722-3-5. [cited 2026 Jul 8];.","journal-title":"J Hematol Oncol [Internet]"},{"key":"3607_CR119","doi-asserted-by":"publisher","unstructured":"Liang T, Wang F, Elhassan RM, Cheng Y, Tang X, Chen W et al. Targeting histone deacetylases for cancer therapy: Trends and challenges. Acta Pharm Sin B [Internet]. Elsevier; 2023 [cited 2026 Jul 8];13:2425\u201363. https:\/\/doi.org\/10.1016\/j.apsb.2023.02.007","DOI":"10.1016\/j.apsb.2023.02.007"},{"key":"3607_CR120","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/14756366.2020.1870457","volume":"36","author":"Y Chen","year":"2021","unstructured":"Chen Y, Zhang L, Zhang L, Jiang Q, Zhang L. Discovery of indole-3-butyric acid derivatives as potent histone deacetylase inhibitors. J Enzyme Inhib Med Chem Taylor Francis Ltd. 2021;36:425\u201336. https:\/\/doi.org\/10.1080\/14756366.2020.1870457.","journal-title":"J Enzyme Inhib Med Chem Taylor Francis Ltd"},{"key":"3607_CR121","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.bioorg.2018.12.011","volume":"84","author":"G Cheng","year":"2019","unstructured":"Cheng G, Wang Z, Yang J, Bao Y, Xu Q, Zhao L, et al. Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC\/BRD4 dual inhibitors and anti-leukemia agents. Bioorg Chem Acad Press Inc. 2019;84:410\u20137. https:\/\/doi.org\/10.1016\/j.bioorg.2018.12.011.","journal-title":"Bioorg Chem Acad Press Inc"},{"key":"3607_CR122","doi-asserted-by":"publisher","first-page":"128846","DOI":"10.1016\/j.bmcl.2022.128846","volume":"72","author":"C Zhu","year":"2022","unstructured":"Zhu C, Liu M, Yuan Y, Chen H, Wu L, Cong Z, et al. Exploration of 4-(1H-indol-3-yl)cyclohex-3-en-1-amine analogues as HDAC inhibitors: Design, synthesis, biological evaluation and modelling studies. Bioorg Med Chem Lett [Internet] Pergamon. 2022;72:128846. https:\/\/doi.org\/10.1016\/j.bmcl.2022.128846. [cited 2026 Jul 8];.","journal-title":"Bioorg Med Chem Lett [Internet] Pergamon"}],"container-title":["Medicinal Chemistry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03607-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00044-026-03607-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03607-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:04:10Z","timestamp":1788343450000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00044-026-03607-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":122,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3607"],"URL":"https:\/\/doi.org\/10.1007\/s00044-026-03607-5","relation":{},"ISSN":["1054-2523","1554-8120"],"issn-type":[{"value":"1054-2523","type":"print"},{"value":"1554-8120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"20 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}